Calamos Advisors LLC grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 6.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,495 shares of the medical research company’s stock after buying an additional 2,309 shares during the period. Calamos Advisors LLC’s holdings in Edwards Lifesciences Corporation were worth $4,788,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of EW. YorkBridge Wealth Partners LLC acquired a new position in shares of Edwards Lifesciences Corporation in the 1st quarter valued at $110,000. NEXT Financial Group Inc boosted its holdings in shares of Edwards Lifesciences Corporation by 91.7% in the 1st quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences Corporation in the 2nd quarter valued at $126,000. Cornerstone Advisors Inc. boosted its holdings in shares of Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares in the last quarter. Finally, Alexandria Capital LLC boosted its holdings in shares of Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares in the last quarter. Institutional investors and hedge funds own 82.36% of the company’s stock.

Several research analysts have recently issued reports on EW shares. Vetr cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 target price for the company. in a report on Monday, May 15th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 target price for the company in a report on Monday, May 22nd. Goldman Sachs Group, Inc. (The) started coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 target price for the company. Barclays PLC upped their target price on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a report on Thursday, July 27th. Finally, Canaccord Genuity restated a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $120.75.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The disclosure for this sale can be found here. Insiders sold 130,641 shares of company stock valued at $15,013,114 in the last ninety days. Corporate insiders own 2.13% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2017/09/07/edwards-lifesciences-corporation-ew-shares-bought-by-calamos-advisors-llc.html.

Edwards Lifesciences Corporation (EW) opened at 112.23 on Thursday. The stock has a market cap of $23.70 billion, a P/E ratio of 34.04 and a beta of 0.64. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The stock has a 50 day moving average of $114.83 and a 200-day moving average of $108.12.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.20. The business had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.76 earnings per share. Analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.